"Why is this significant?

T-cell cancer therapies already exist and the development of cancer immunotherapy has been one of the most exciting advances in the field.

The most famous example is CAR-T - a living drug made by genetically engineering a patient's T-cells to seek out and destroy cancer.

CAR-T can have dramatic results that transform some patients from being terminally ill to being in complete remission.

However, the approach is highly specific and works in only a limited number of cancers where there is a clear target to train the T-cells to spot.

And it has struggled to have any success in "solid cancers" - those that form tumours rather than blood cancers such as leukaemia.

The researchers say their T-cell receptor could lead to a "universal" cancer treatment."

To eksisterende terapier, der begge koster i omegnen af en halv million dollar, er:

Yescarta fra Kite Pharma (nu Gilead Sciences)
https://en.wikipedia.org/wiki/Axicabtagene_ciloleucel
https://www.yescarta.com/

Kymriah fra Novartis
https://en.wikipedia.org/wiki/Tisagenlecleucel
https://www.kymriah.com/